Gilead Sciences, Inc. (GILD) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gilead Non-GAAP diluted EPS attributable to Gilead | 2.03 USD_per_share | FY2026-Q1 |
| Product gross margin (non-GAAP) | 87.50 percent | FY2026-Q1 |
| Gilead Trodelvy | 402M | FY2026-Q1 |
| Yescarta sales | 332M | FY2026-Q1 |
| Biktarvy sales | 3.4B | FY2026-Q1 |
| Descovy sales | 807M | FY2026-Q1 |
| HIV product sales | 5.03B | FY2026-Q1 |
| Oncology product sales | 810M | FY2026-Q1 |
| Non-GAAP net income attributable to Gilead | 2.33B | FY2025-Q4 |
| Gilead Veklury | 277M | FY2025-Q3 |
| Product sales excluding Veklury | 7.1B | FY2025-Q3 |
| Tecartus sales | 83M | FY2025-Q3 |
| Liver Disease portfolio sales | 819M | FY2025-Q3 |
| Cell Therapy product sales | 432M | FY2025-Q3 |
Back to GILD overview · GILD earnings · GILD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.